4th mRNA Analytical Development and Quality Control Summit

Memo

With RNA technologies receiving the Nobel Prize two years running, we are witnessing the mRNA industry make great strides as optimized analytics, critical quality control methodology and robust assay development lead to efficient approvals and commercialization. However, developing, validating and transferring methods to demonstrate drug substance and product CQAs remains no easy feat, as knowledge gaps persist in phase appropriate potency assays, analyzing LNP payloads and novel cell-targeted delivery systems, controlling dsRNA, and navigating the global mRNA therapeutics and vaccine regulatory seas for approval in unmet patient need. For the very first time, the 4th mRNA Analytical Development and Quality Control Summit will unite the tightly knit assay development, analytical and quality control communities, providing these technical teams with the means to secure regulatory submissions for 2025 and beyond. URLs:Tickets: https://go.evvnt.com/2713888-2?pid=5569 Brochure: https://go.evvnt.com/2713888-3?pid=5569 Date and Time: On Tue, 25 Feb 2025 08:00 - Thu, 27 Feb 2025 16:30 Venue Details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States Prices:Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4297.00,Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2999.00,Academic and Not-For-Profit Pricing - 3 Day Pass (Conference + Workshop Day): USD 3697.00,Academic and Not-For-Profit Pricing - 2 Day Pass (Conference Only): USD 2599.00,Service and Solution Providers Pricing - 3 Day Pass (Conference + Workshop Day): USD 5197.00,Service and Solution Providers Pricing - 2 Day Pass (Conference Only): USD 3699.00 Speakers: Zhanyong (James) Shu, Vice President, Analytical Science, Abogen Biosciences, Srujan Gandham, Associate Director, Analytical Development, Aera Therapeutics, Zack Zhang, Director, Analytical Development, Beam Therapeutics, Jan Michel, Falcke Director Global AS and T, BioNTech, Emnet Yitbarek, Scientist, FDA, Juan Bian, Principal Scientist, Genentech, Diana Posadas, Director, Strategic Research, Greenlight Biosciences, Rameh Hafezi, Associate Director, Analytical Technologies, Gritstone Bio, Ajit Magadum, Assistant Professor, Lewis Katz School of Medicine at Temple University, Glenn Milton, Senior Scientist, Analytical Development, Moderna, Mehdi Shirzadeh, Senior Scientist, Analytical Development, Moderna, Joyce Zhao, Director, Head of Analytical Science, Myeloid Therapeutics, Chris Broomell, Head of Analytical Development, Omega Therapeutics, Thareendra De Zoysa, Scientist, Orna Therapeutics, Erin Wierzbicki, Senior Manager, GCMC Regulatory Affairs, mRNA Vaccines, Pfizer, Kelly Sackett, Senior Principal Scientist, Pfizer, Rebecca Malott, Senior Manager, Analytical Providence, Therapeutics, Elisha Fielding, Director, Sail Biomedicines, Dinesh Manvar, Associate Director, Analytical Development, Sail Biomedicines, Lusheng Fan, Senior Scientist, Sanofi, Anna Dudkina, Director, Analytical Development, Tessera Therapeutics, Jonathan Maurer, Post-Doctoral Researcher, University of Geneva and Sanofi, Jason Zhang, Co-Founder and Chief Executive Officer, Zipcode Bio